Literature DB >> 12900383

In vivo stimulation of sympathetic nervous system modulates osteoblastic activity in mouse calvaria.

Ayami Kondo1, Akifumi Togari.   

Abstract

Previously, we demonstrated that epinephrine induced the expression of interleukin (IL)-6 mRNA via beta-adrenoceptors in cultured human osteoblastic cells. IL-6 is well known to modulate bone metabolism by regulating the development and function of osteoclasts and osteoblasts. Recently, restraint stress and intracerebroventricular injection of lipopolysaccharide (LPS) have been reported to induce the expression of IL-6 mRNA in peripheral organs in mice in which expression is mediated by the activation of the sympathetic nervous system. To prove the physiological role of sympathetic nerves in bone metabolism in vivo, we examined by RT-PCR analysis the effects of restraint stress and intracerebroventricular injection of LPS on IL-6 mRNA expression in mouse calvaria. The expression of IL-6 mRNA in mouse calvaria was stimulated by either restraint stress (30 min) or intracerebroventricular injection of LPS (50 ng/mouse, 60 min). The treatment of mice with the neurotoxin 6-hydroxydopamine (6-OHDA, 100 mg x kg-1 x day-1 ip for 3 days) inhibited LPS (icv)-induced expression of IL-6 mRNA in their calvaria. The expression of IL-6 mRNA induced by the restraint stress was not influenced by 6-OHDA, which destroys noradrenergic nerve terminals. Furthermore, pretreatment with a beta-blocker, propranolol (15 or 25 mg/kg ip), inhibited both stress- and LPS-induced increases in the level of IL-6 mRNA, but pretreatment with an alpha-blocker, phentolamine (5 mg/kg sc), did not inhibit them in mouse calvaria. In addition, treatment of calvaria with isoprenaline or norepinephrine increased IL-6 synthesis in the organ culture system. These results indicate that in vivo adrenergic stimulation modulates the osteoblastic activity in mouse calvaria via noradrenergic nerve terminals.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12900383     DOI: 10.1152/ajpendo.00026.2003

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  6 in total

1.  Duodenal calcium transporter mRNA expression in stressed male rats treated with diazepam, fluoxetine, reboxetine, or venlafaxine.

Authors:  Narattaphol Charoenphandhu; Jarinthorn Teerapornpuntakit; Sarawut Lapmanee; Nateetip Krishnamra; Jantarima Charoenphandhu
Journal:  Mol Cell Biochem       Date:  2012-07-06       Impact factor: 3.396

2.  Low dose of propranolol down-modulates bone resorption by inhibiting inflammation and osteoclast differentiation.

Authors:  W F Rodrigues; M F M Madeira; T A da Silva; J T Clemente-Napimoga; C B Miguel; V J Dias-da-Silva; O Barbosa-Neto; A H Lopes; M H Napimoga
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  Parkinson's disease and osteoporosis: basic and clinical implications.

Authors:  Carolina A Figueroa; Clifford J Rosen
Journal:  Expert Rev Endocrinol Metab       Date:  2020-04-26

4.  Liposomal Encapsulation for Systemic Delivery of Propranolol via Transdermal Iontophoresis Improves Bone Microarchitecture in Ovariectomized Rats.

Authors:  Benjamin Teong; Shyh Ming Kuo; Wei-Hsin Tsai; Mei-Ling Ho; Chung-Hwan Chen; Han Hsiang Huang
Journal:  Int J Mol Sci       Date:  2017-04-13       Impact factor: 5.923

5.  Blockade of adrenergic β-receptor activation through local delivery of propranolol from a 3D collagen/polyvinyl alcohol/hydroxyapatite scaffold promotes bone repair in vivo.

Authors:  Hao Wu; Yue Song; Junqin Li; Xing Lei; Shuaishuai Zhang; Yi Gao; Pengzhen Cheng; Bin Liu; Sheng Miao; Long Bi; Liu Yang; Guoxian Pei
Journal:  Cell Prolif       Date:  2019-11-20       Impact factor: 6.831

6.  Olfactory regulation by dopamine and DRD2 receptor in the nose.

Authors:  Hai-Qian Zhou; Liu-Jing Zhuang; Hong-Qiang Bao; Sheng-Ju Li; Feng-Yan Dai; Ping Wang; Qian Li; Dong-Min Yin
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-09       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.